1 citations · 1 across the 8 of their papers we have counts for
9 papers
Joint TITE-CRM for Dual Agent Dose Finding Studies
Helen Barnett, Oliver Boix, Dimitris Kontos +1
Dual agent dose-finding trials study the effect of a combination of more than one agent, where the objective is to find the Maximum Tolerated Dose Combination (MTC), the combinatio…
How to Add Baskets to an Ongoing Basket Trial with Information Borrowing
Libby Daniells, Pavel Mozgunov, Helen Barnett +2
Basket trials test a single therapeutic treatment on several patient populations under one master protocol. A desirable adaptive design feature in these studies may be the incorpor…
Bayesian Model Averaging for Partial Ordering Continual Reassessment Methods
Luka Kovacevic, Thomas Jaki, Helen Barnett +1
Phase I clinical trials are essential to bringing novel therapies from chemical development to widespread use. Traditional approaches to dose-finding in Phase I trials, such as the…
Backfilling Cohorts in Phase I Dose-Escalation Studies
Helen Barnett, Oliver Boix, Dimitris Kontos +1
The use of `backfilling', assigning additional patients to doses deemed safe, in phase I dose-escalation studies has been used in practice to collect additional information on the…
Dose Finding Studies for Therapies with Late-Onset Safety and Efficacy Outcomes
Helen Barnett, Oliver Boix, Dimitris Kontos +1
In Phase I/II dose-finding trials, the objective is to find the Optimal Biological Dose (OBD), a dose that is both safe and efficacious that maximises some optimality criterion bas…
Dose Finding Studies for Therapies with Late-Onset Toxicities: A Comparison Study of Designs
Helen Barnett, Oliver Boix, Dimintris Kontos +1
An objective of phase I dose-finding trials is to find the maximum tolerated dose; the dose with a particular risk of toxicity. Frequently, this risk is assessed across the first c…
A Comparison of Model-Free Phase I Dose Escalation Designs for Dual-Agent Combination Therapies
Helen Yvette Barnett, Matthew George, Donia Skanji +3
It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the ri…
A Novel Statistical Test for Treatment Differences in Clinical Trials using a Response Adaptive Forward Looking Gittins Index Rule
Helen Yvette Barnett, Sofia S Villar, Helena Geys +1
The most common objective for response adaptive clinical trials is to seek to ensure that patients within a trial have a high chance of receiving the best treatment available by al…
A Seamless Phase I/II Platform Design with a Time-To-Event Efficacy Endpoint for Potential COVID-19 Therapies
Thomas Jaki, Helen Barnett, Andrew Titman +1
In the search for effective treatments for COVID-19, initial emphasis has been on re-purposed treatments. To maximise the chances of finding successful treatments, novel treatments…